TY - JOUR
T1 - New approach methods to assess developmental and adult neurotoxicity for regulatory use
T2 - a PARC work package 5 project
AU - Tal, Tamara
AU - Myhre, Oddvar
AU - Fritsche, Ellen
AU - Rüegg, Joëlle
AU - Craenen, Kai
AU - Aiello-Holden, Kiara
AU - Agrillo, Caroline
AU - Babin, Patrick J
AU - Escher, Beate I
AU - Dirven, Hubert
AU - Hellsten, Kati
AU - Dolva, Kristine
AU - Hessel, Ellen
AU - Heusinkveld, Harm J
AU - Hadzhiev, Yavor
AU - Hurem, Selma
AU - Jagiello, Karolina
AU - Judzinska, Beata
AU - Klüver, Nils
AU - Knoll-Gellida, Anja
AU - Kühne, Britta A
AU - Leist, Marcel
AU - Lislien, Malene
AU - Lyche, Jan L
AU - Müller, Ferenc
AU - Colbourne, John K
AU - Neuhaus, Winfried
AU - Pallocca, Giorgia
AU - Seeger, Bettina
AU - Scharkin, Ilka
AU - Scholz, Stefan
AU - Spjuth, Ola
AU - Torres-Ruiz, Monica
AU - Bartmann, Kristina
N1 - Copyright © 2024 Tal, Myhre, Fritsche, Rüegg, Craenen, Aiello-Holden, Agrillo, Babin, Escher, Dirven, Hellsten, Dolva, Hessel, Heusinkveld, Hadzhiev, Hurem, Jagiello, Judzinska, Klüver, Knoll-Gellida, Kühne, Leist, Lislien, Lyche, Müller, Colbourne, Neuhaus, Pallocca, Seeger, Scharkin, Scholz, Spjuth, Torres-Ruiz and Bartmann.
PY - 2024/4/26
Y1 - 2024/4/26
N2 - In the European regulatory context, rodent in vivo studies are the predominant source of neurotoxicity information. Although they form a cornerstone of neurotoxicological assessments, they are costly and the topic of ethical debate. While the public expects chemicals and products to be safe for the developing and mature nervous systems, considerable numbers of chemicals in commerce have not, or only to a limited extent, been assessed for their potential to cause neurotoxicity. As such, there is a societal push toward the replacement of animal models with in vitro or alternative methods. New approach methods (NAMs) can contribute to the regulatory knowledge base, increase chemical safety, and modernize chemical hazard and risk assessment. Provided they reach an acceptable level of regulatory relevance and reliability, NAMs may be considered as replacements for specific in vivo studies. The European Partnership for the Assessment of Risks from Chemicals (PARC) addresses challenges to the development and implementation of NAMs in chemical risk assessment. In collaboration with regulatory agencies, Project 5.2.1e (Neurotoxicity) aims to develop and evaluate NAMs for developmental neurotoxicity (DNT) and adult neurotoxicity (ANT) and to understand the applicability domain of specific NAMs for the detection of endocrine disruption and epigenetic perturbation. To speed up assay time and reduce costs, we identify early indicators of later-onset effects. Ultimately, we will assemble second-generation developmental neurotoxicity and first-generation adult neurotoxicity test batteries, both of which aim to provide regulatory hazard and risk assessors and industry stakeholders with robust, speedy, lower-cost, and informative next-generation hazard and risk assessment tools.
AB - In the European regulatory context, rodent in vivo studies are the predominant source of neurotoxicity information. Although they form a cornerstone of neurotoxicological assessments, they are costly and the topic of ethical debate. While the public expects chemicals and products to be safe for the developing and mature nervous systems, considerable numbers of chemicals in commerce have not, or only to a limited extent, been assessed for their potential to cause neurotoxicity. As such, there is a societal push toward the replacement of animal models with in vitro or alternative methods. New approach methods (NAMs) can contribute to the regulatory knowledge base, increase chemical safety, and modernize chemical hazard and risk assessment. Provided they reach an acceptable level of regulatory relevance and reliability, NAMs may be considered as replacements for specific in vivo studies. The European Partnership for the Assessment of Risks from Chemicals (PARC) addresses challenges to the development and implementation of NAMs in chemical risk assessment. In collaboration with regulatory agencies, Project 5.2.1e (Neurotoxicity) aims to develop and evaluate NAMs for developmental neurotoxicity (DNT) and adult neurotoxicity (ANT) and to understand the applicability domain of specific NAMs for the detection of endocrine disruption and epigenetic perturbation. To speed up assay time and reduce costs, we identify early indicators of later-onset effects. Ultimately, we will assemble second-generation developmental neurotoxicity and first-generation adult neurotoxicity test batteries, both of which aim to provide regulatory hazard and risk assessors and industry stakeholders with robust, speedy, lower-cost, and informative next-generation hazard and risk assessment tools.
U2 - 10.3389/ftox.2024.1359507
DO - 10.3389/ftox.2024.1359507
M3 - Article
C2 - 38742231
SN - 2673-3080
VL - 6
SP - 1359507
JO - Frontiers in Toxicology
JF - Frontiers in Toxicology
ER -